Bezafibrate induces FALDH in human fibroblasts; implications for Sjögren-Larsson syndrome

Molecular Genetics and Metabolism

Volumn 89, Issue 1-2, 2006, Pages 111-115

  Gloerich, J ^a   IJlst, L ^a   Wanders, R J A ^a   Ferdinandusse, S ^a  

^a EMMA CHILDREN S HOSPITAL   (Netherlands)

Author keywords

Bezafibrate; Fatty aldehyde dehydrogenase; Peroxisome proliferator activated receptors; Sj gren Larsson syndrome

Indexed keywords

ALDEHYDE DEHYDROGENASE; BEZAFIBRATE; MESSENGER RNA;

ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; FIBROBLAST; HOMOZYGOSITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA ANALYSIS; SJOEGREN LARSSON SYNDROME; SUBSTITUTION REACTION;

ALDEHYDE OXIDOREDUCTASES; ANTILIPEMIC AGENTS; BEZAFIBRATE; CELLS, CULTURED; FIBROBLASTS; HUMANS; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; SJOGREN-LARSSON SYNDROME; UP-REGULATION;

ANIMALIA; MURINAE;

EID: 33747158540     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2006.05.009     Document Type: Article

References (31)

1. Willemsen M.A., IJlst L., Steijlen P.M., Rotteveel J.J., de Jong J.G., van Domburg P.H., Mayatepek E., Gabreels F.J., and Wanders R.J. Clinical, biochemical and molecular genetic characteristics of 19 patients with the Sjogren-Larsson syndrome. Brain 124 (2001) 1426-1437
2. + oxidoreductase in cultured fibroblasts. J. Clin. Invest. 88 (1991) 1643-1648
3. Rizzo W.B., and Craft D.A. Sjogren-Larsson syndrome: accumulation of free fatty alcohols in cultured fibroblasts and plasma. J. Lipid Res. 41 (2000) 1077-1081
4. Willemsen M.A., Rotteveel J.J., de Jong J.G., Wanders R.J., IJlst L., Hoffmann G.F., and Mayatepek E. Defective metabolism of leukotriene B4 in the Sjogren-Larsson syndrome. J. Neurol. Sci. 183 (2001) 61-67
5. van den Brink D.M., van Miert J.N., Dacremont G., Rontani J.F., Jansen G.A., and Wanders R.J. Identification of fatty aldehyde dehydrogenase in the breakdown of phytol to phytanic acid. Mol. Genet. Metab. 82 (2004) 33-37
6. Savolainen K., Kotti T.J., Schmitz W., Savolainen T.I., Sormunen R.T., Ilves M., Vainio S.J., Conzelmann E., and Hiltunen J.K. A mouse model for {alpha}-methylacyl-CoA racemase deficiency: adjustment of bile acid synthesis and intolerance to dietary methyl-branched lipids. Hum. Mol. Genet. 13 (2004) 955-965
7. Baes M., Huyghe S., Carmeliet P., Declercq P.E., Collen D., Mannaerts G.P., and Van Veldhoven P.P. Inactivation of the peroxisomal multifunctional protein-2 in mice impedes the degradation of not only 2-methyl-branched fatty acids and bile acid intermediates but also of very long chain fatty acids. J. Biol. Chem. 275 (2000) 16329-16336
8. Gloerich J., Van Vlies N., Jansen G.A., Denis S., Ruiter J.P., van Werkhoven M.A., Duran M., Vaz F.M., Wanders R.J., and Ferdinandusse S. A phytol-enriched diet induces changes in fatty acid metabolism in mice both via PPARα-dependent and -independent pathways. J. Lipid Res. 46 (2005) 716-726
9. Ellinghaus P., Wolfrum C., Assmann G., Spener F., and Seedorf U. Phytanic acid activates the peroxisome proliferator-activated receptor alpha (PPARα) in sterol carrier protein 2-/sterol carrier protein x-deficient mice. J. Biol. Chem. 274 (1999) 2766-2772
10. Heim M., Johnson J., Boess F., Bendik I., Weber P., Hunziker W., and Fluhmann B. Phytanic acid, a natural peroxisome proliferator-activated receptor (PPAR) agonist, regulates glucose metabolism in rat primary hepatocytes. FASEB J. 16 (2002) 718-720
11. Zomer A.W., Van der Burg B., Jansen G.A., Wanders R.J., Poll-The B.T., and Van der Saag P.T. Pristanic acid and phytanic acid: naturally occurring ligands for the nuclear receptor peroxisome proliferator-activated receptor alpha. J. Lipid Res. 41 (2000) 1801-1807
12. Mandard S., Muller M., and Kersten S. Peroxisome proliferator-activated receptor alpha target genes. Cell Mol. Life Sci. 61 (2004) 393-416
13. Berger J., and Moller D.E. The mechanisms of action of PPARs. Annu. Rev. Med. 53 (2002) 409-435
14. Braissant O., Foufelle F., Scotto C., Dauca M., and Wahli W. Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology 137 (1996) 354-366
15. Reddy J.K., and Hashimoto T. Peroxisomal beta-oxidation and peroxisome proliferator-activated receptor alpha: an adaptive metabolic system. Annu. Rev. Nutr. 21 (2001) 193-230
16. Barbier O., Torra I.P., Duguay Y., Blanquart C., Fruchart J.C., Glineur C., and Staels B. Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 22 (2002) 717-726
17. Vamecq J., and Latruffe N. Medical significance of peroxisome proliferator-activated receptors. Lancet 354 (1999) 141-148
18. van den Brink D.M., van Miert J.M., and Wanders R.J. Assay for Sjogren-Larsson syndrome based on a deficiency of phytol degradation. Clin. Chem. 51 (2005) 240-242
19. Gootjes J., Schmohl F., Waterham H.R., and Wanders R.J. Novel mutations in the PEX12 gene of patients with a peroxisome biogenesis disorder. Eur. J. Hum. Genet. 12 (2004) 115-120
20. Ramakers C., Ruijter J.M., Deprez R.H., and Moorman A.F. Assumption-free analysis of quantitative real-time polymerase chain reaction (PCR) data. Neurosci. Lett. 339 (2003) 62-66
21. De Laurenzi V., Rogers G.R., Hamrock D.J., Marekov L.N., Steinert P.M., Compton J.G., Markova N., and Rizzo W.B. Sjogren-Larsson syndrome is caused by mutations in the fatty aldehyde dehydrogenase gene. Nat. Genet. 12 (1996) 52-57
22. De Laurenzi V., Rogers G.R., Tarcsa E., Carney G., Marekov L., Bale S.J., Compton J.G., Markova N., Steinert P.M., and Rizzo W.B. Sjogren-Larsson syndrome is caused by a common mutation in northern European and Swedish patients. J. Invest. Dermatol. 109 (1997) 79-83
23. Rizzo W.B., Carney G., and De Laurenzi V. A common deletion mutation in European patients with Sjogren-Larsson syndrome. Biochem. Mol. Med. 62 (1997) 178-181
24. Sillen A., Anton-Lamprecht I., Braun-Quentin C., Kraus C.S., Sayli B.S., Ayuso C., Jagell S., Kuster W., and Wadelius C. Spectrum of mutations and sequence variants in the FALDH gene in patients with Sjogren-Larsson syndrome. Hum. Mutat. 12 (1998) 377-384
25. Tsukamoto N., Chang C., and Yoshida A. Mutations associated with Sjogren-Larsson syndrome. Ann. Hum. Genet. 61 Pt 3 (1997) 235-242
26. Sillen A., Jagell S., and Wadelius C. A missense mutation in the FALDH gene identified in Sjogren-Larsson syndrome patients originating from the northern part of Sweden. Hum. Genet. 100 (1997) 201-203
27. Rizzo W.B., Carney G., and Lin Z. The molecular basis of Sjogren-Larsson syndrome: mutation analysis of the fatty aldehyde dehydrogenase gene. Am. J. Hum. Genet. 65 (1999) 1547-1560
28. Willemsen M.A., Steijlen P.M., de Jong J.G., Rotteveel J.J., IJlst L., van Werkhoven M.A., and Wanders R.J. A novel 4 bp deletion mutation in the FALDH gene segregating in a Turkish family with Sjogren-Larsson syndrome. J. Invest. Dermatol. 112 (1999) 827-828
29. Aoki N., Suzuki H., Ito K., and Ito M. A novel point mutation of the FALDH gene in a Japanese family with Sjogren-Larsson syndrome. J. Invest. Dermatol. 114 (2000) 1065-1066
30. Kraus C., Braun-Quentin C., Ballhausen W.G., and Pfeiffer R.A. RNA-based mutation screening in German families with Sjogren-Larsson syndrome. Eur. J. Hum. Genet. 8 (2000) 299-306
31. Maquat L.E. Defects in RNA splicing and the consequence of shortened translational reading frames. Am. J. Hum. Genet. 59 (1996) 279-286